Site Editors
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Posted: Monday, April 15, 2024
Linvoseltamab induced responses in patients with relapsed or refractory multiple myeloma, according to recent pivotal results of the LINKER-MM1 clinical trial. The agent, a bispecific antibody, targets both B-cell maturation antigen and CD3-expressing T cells, noted Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai, New York, and colleagues. The team presented their work on the 117 patients in the 200-mg dosing cohorts (phases I and II) during the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT001).
For these cohorts at data cutoff, the overall response rate—the primary outcome—was 71%, which included a complete response or better rate of 46%. Among all patients with a complete response or better, 39% had achieved undetectable measurable residual disease (MRD). Significantly, frequent deep responses were observed across high-risk subgroups, including patients with stage III disease (representing 18% of the cohorts’ patients) and those with extramedullary (excluding paramedullary) plasmacytomas of 2 cm or greater (16% of the patients): overall response rate, 62% and 53%, respectively; complete response or better, 43% and 26%, respectively. Additionally, the patients’ median age was 70, 17% were Black, 39% had high-risk cytogenetics, and 82% had triple-class–refractory disease.
In terms of safety, cytokine-release syndrome occurred with generally predictable timing with use of linvoseltamab, according to the study authors. Any-grade cytokine-release sundrome occurred in nearly half of treated patients (46%). Additionally, an every-4-weeks response–adapted schedule in patients who achieved a very good partial response or better after 24 weeks of intravenous linvoseltamab (first every week, then every 2 weeks) “may provide a substantial benefit for patient convenience and is associated with a reduced infection rate,” they noted. Infections occurred in 73% of patients, with grade 3 or 4 infections reported in 34%.
The median duration of follow-up was 11.1 months. Estimated probabilities at 12 months of ongoing response, progression-free survival, and overall survival were 78%, 69%, and 75%, respectively.
Disclosure: For full disclosures of the study authors, visit abstractsonline.com.
